CAJ | 학술논문

收集接受硼替佐米+地塞米松+沙利度胺( BDT)方案化疗的25例多发性骨髓瘤( MM)患者的临床信息，对其疗效、相关影响因素及不良反应进行回顾性分析及评价。以硼替佐米为基础的化疗方案治疗25例 MM 患者的总有效( OR )率为80．00%(20/25)，其中完全缓解( CR )9例(36．00%)，非常好的部分缓解(VGPR)6例(24．00%)，部分缓解( PR)5例(20．00%)；复发/难治性MM患者与新诊断MM患者的疗效相当( OR 率：62．5% vs 88．24%， P >0．05)；国际分期系统( ISS)Ⅰ+Ⅱ期患者疗效与Ⅲ期患者疗效差异无统计学意义( OR 率：83．33% vs 76．92%；P >0．05)；长疗程(≥4个疗程)化疗组患者的CR率明显高于短疗程(3、2、1个疗程)化疗组患者(77．78% vs 30．77% vs 15．79% vs 4．00%)；浆细胞白血病及严重肾功能损害的MM&nbsp；瘤可获得VGPR以上疗效；主要不良反应包括周围神经病变、胃肠道反应、血小板减少、粒细胞缺乏、皮疹等，经过对症治疗以及调整剂量后均能改善。
수집접수붕체좌미+지새미송+사리도알( BDT)방안화료적25례다발성골수류( MM)환자적림상신식，대기료효、상관영향인소급불량반응진행회고성분석급평개。이붕체좌미위기출적화료방안치료25례 MM 환자적총유효( OR )솔위80．00%(20/25)，기중완전완해( CR )9례(36．00%)，비상호적부분완해(VGPR)6례(24．00%)，부분완해( PR)5례(20．00%)；복발/난치성MM환자여신진단MM환자적료효상당( OR 솔：62．5% vs 88．24%， P >0．05)；국제분기계통( ISS)Ⅰ+Ⅱ기환자료효여Ⅲ기환자료효차이무통계학의의( OR 솔：83．33% vs 76．92%；P >0．05)；장료정(≥4개료정)화료조환자적CR솔명현고우단료정(3、2、1개료정)화료조환자(77．78% vs 30．77% vs 15．79% vs 4．00%)；장세포백혈병급엄중신공능손해적MM&nbsp；류가획득VGPR이상료효；주요불량반응포괄주위신경병변、위장도반응、혈소판감소、립세포결핍、피진등，경과대증치료이급조정제량후균능개선。
The clinical features of all 25 multiple myeloma ( MM ) patients who were treated with BDT regimen ( bortezomib and dexamethasone and thalidomide) were recruited. The efficacy and related influence factors and ad-verse drug reactions were retrospectively evaluated. The overall remission(OR) rate was 80. 00%(20/25) and the complete remission (CR) rate was 36. 00% (9/25),very good partial remission (VGPR) and partial remission (PR) rate were 24. 00% (6/25) and 20. 00%(5/25) respectively in MM patients with BDT regimen. The OR rate of relapsing/refractory MM patients was not statistically lower than that of newly-diagnosed MM patients (62. 5% vs 88. 24%,P>0. 05). The OR rate of ISSⅢstage patients was as better as that of ISS I andⅡstage pa-tients(83. 33% vs 76. 92%, P>0. 05). The CR rate of the arm who received many cycle regimens(≥4 cycles) was higher than that of the arm who received 4 cycles regimens(3,2,1 cycles),but there was no statistically signifi-cant difference. The patients with plasma cell leukemia and renal failure were treated with bortezomib based regi-men and achieved PR or above. The main adverse effects were peripheral neuropathy,gastrointestinal symptoms, thrombocytopenia,neutropenia,skin rash,et al. All adverse events were diminished by using routine ways.